Danville, Pa.-based Geisinger and Rochester, Minn.-based Mayo Clinic supply genetic data to biotechnology company Regeneron to aid its drug discovery efforts, according to The Wall Street Journal.
Below are six genetic databases and their drug industry partners:
1. 23andMe — which has genetic data from about 5 million individuals — partners with Genentech and GlaxoSmithKline.
2. deCODE Genetics — which has data from about 1.6 million people — partners with Amgen.
3. UK Biobank — which has data from 500,000 people — partners with AbbVie, Alnylam, AstraZeneca, Biogen, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Regeneron and Takeda.
4. Geisinger — which supplies data from 250,000 people — partners with Regeneron.
5. Mayo Clinic — which supplies data from 100,000 people — partners with Regeneron.
6. FinnGen — which has data from about 147,000 people — partners with AbbVie, AstraZeneca, Biogen, Celgene, Genentech, GlaxoSmithKline, Merck & Co., Pfizer and Sanofi.
More articles on pharmacy:
Oklahoma opioid trial wraps: 10 takeaways
Drugmaker tried to shred records before FDA inspection, agency claims
Publix Pharmacy to deliver prescriptions to patients before hospital discharge